Raldesy

Dosage for Trazodone must be individualized based on the condition being treated and the patient's response to the medication. Healthcare providers typically start with a low dose and gradually increase it (titration) to minimize side effects.

• Major Depressive Disorder: The typical starting dose for outpatients is 150 mg per day, divided into two or three doses. This may be increased by 50 mg per day every 3 to 7 days. The maximum dose for outpatients is generally 400 mg per day, while hospitalized patients with severe depression may receive up to 600 mg per day in divided doses.
• Insomnia (Off-label): For sleep disturbances, healthcare providers often prescribe much lower doses, typically ranging from 25 mg to 100 mg, taken once daily at bedtime.

Trazodone is not currently FDA-approved for use in pediatric patients (children and adolescents under 18 years of age). Clinical trials have not established the safety and efficacy of Trazodone in this population. Furthermore, Trazodone carries a black box warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressant medications.

Renal Impairment

Specific dosage adjustments for patients with kidney disease are not provided in the standard labeling; however, since the majority of Trazodone metabolites are excreted renally, healthcare providers should exercise caution and monitor these patients closely for increased side effects.

Hepatic Impairment

Because Trazodone is extensively metabolized by the liver, patients with significant hepatic impairment (liver disease) may require lower doses or slower titration schedules. Frequent monitoring of liver function tests may be necessary.

Elderly Patients

Older adults are more sensitive to the sedative and hypotensive effects of Trazodone. Healthcare providers typically start elderly patients at the lowest possible dose (e.g., 25 mg to 50 mg) and increase very slowly to prevent falls and confusion.

• Timing: For depression, Trazodone is usually taken in divided doses throughout the day. If significant drowsiness occurs, your doctor may suggest taking the largest portion of the daily dose at bedtime. For insomnia, it should be taken 30 to 60 minutes before your planned sleep time.
• Food: Trazodone should be taken shortly after a meal or a light snack. Taking the medication on an empty stomach increases the risk of dizziness, lightheadedness, and nausea.
• Administration: Immediate-release tablets can be split if they are scored. Extended-release tablets must be swallowed whole; do not crush, chew, or break them, as this can cause the entire dose to be released into your system at once, increasing the risk of toxicity.
• Storage: Store Trazodone at room temperature (68°F to 77°F or 20°C to 25°C) in a dry place, away from direct sunlight and moisture.

If you miss a dose of Trazodone, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not double the dose to catch up, as this significantly increases the risk of adverse effects like extreme drowsiness or low blood pressure.

An overdose of Trazodone can be life-threatening, especially when combined with alcohol or other CNS depressants.

Signs of overdose include:

• Extreme drowsiness or coma
• Priapism (prolonged, painful erection)
• Seizures
• Respiratory arrest (stopping breathing)
• Cardiac arrhythmias (irregular heartbeat), including QT prolongation
• Vomiting

In the event of a suspected overdose, call 911 or your local emergency services immediately. Emergency room management typically involves gastric lavage (stomach pumping), administration of activated charcoal, and supportive care to maintain heart and lung function.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can lead to withdrawal symptoms.

Most patients taking Trazodone will experience some mild side effects, which often diminish as the body adjusts to the medication. Common effects include:

• Somnolence (Drowsiness): This is the most frequent side effect. It can feel like a heavy 'fog' or extreme sleepiness during the day. This is why the drug is often dosed at night.
• Xerostomia (Dry Mouth): A sensation of dryness in the mouth or throat. Staying hydrated and using sugar-free lozenges can help.
• Dizziness and Lightheadedness: Particularly when rising from a sitting or lying position (orthostatic hypotension).
• Nausea: Often described as a mild 'upset stomach,' which is usually mitigated by taking the drug with food.

• Blurred Vision: Difficulty focusing the eyes, which usually resolves with time.
• Constipation or Diarrhea: Changes in bowel habits.
• Myalgia (Muscle Aches): General body aches or stiffness.
• Nervousness or Tremor: A feeling of 'jitteriness' or slight shaking of the hands.
• Syncope (Fainting): Often related to a sudden drop in blood pressure.

• Hyponatremia: Low sodium levels in the blood, which can cause confusion, headaches, and in severe cases, seizures. This is more common in elderly patients taking diuretics.
• Neutropenia: A decrease in white blood cell count, which may increase the risk of infection.
• Hepatotoxicity: Rare instances of liver enzyme elevation or jaundice (yellowing of the skin/eyes).

> Warning: Stop taking Trazodone and call your doctor or emergency services immediately if you experience any of the following:

• Priapism: This is a medical emergency. It involves a persistent, painful erection of the penis unrelated to sexual activity that lasts longer than 4 hours. If not treated immediately, it can lead to permanent erectile dysfunction or tissue damage.
• Serotonin Syndrome: A potentially fatal condition caused by too much serotonin. Symptoms include high fever, agitation, shivering, fast heart rate, muscle rigidity, and hallucinations.
• Suicidal Thoughts: Especially in patients under age 25, any new or worsening thoughts of self-harm or suicide must be reported immediately.
• Cardiac Arrhythmias: Feeling like your heart is skipping a beat, racing, or fluttering.
• Severe Allergic Reaction: Hives, swelling of the face, tongue, or throat, and difficulty breathing.
• Angle-Closure Glaucoma: Eye pain, changes in vision, or swelling/redness in or around the eye.

With prolonged use, some patients may experience weight changes (either gain or loss), though Trazodone is generally considered more weight-neutral than many other antidepressants. There is also a risk of developing a tolerance to the sedative effects, meaning the drug may become less effective for sleep over time. Long-term use requires periodic monitoring of liver and kidney function by a healthcare professional.

Suicidality and Antidepressant Drugs:

Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults (ages 18-24) in short-term studies of Major Depressive Disorder and other psychiatric disorders. This risk was not seen in patients over age 24. Patients of all ages who are started on Trazodone therapy should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.

Report any unusual symptoms or side effects to your healthcare provider promptly to ensure your treatment plan remains safe and effective.

Trazodone is a potent medication that affects the central nervous system. It is vital to understand that this medication does not work immediately for depression; it may take 2 to 4 weeks to feel the full therapeutic effect. During this initial period, patients must be monitored closely for any changes in mood or behavior.

Full FDA Text Summary: Trazodone carries a boxed warning regarding the increased risk of suicidal thinking and behavior in children, adolescents, and young adults. Healthcare providers must weigh this risk against the clinical need. Trazodone is not approved for use in pediatric patients. Families should watch for signs such as agitation, irritability, or any unusual changes in behavior, especially during the first few months of treatment or during dose adjustments.

• Priapism Risk: As noted in the side effects section, Trazodone has been associated with priapism. Men should be informed of this rare but serious risk and instructed to seek immediate medical attention if an erection lasts more than 4 hours.
• Cardiovascular Risks: Trazodone can cause QT prolongation, a condition that affects the heart's electrical rhythm. This can lead to serious, potentially fatal arrhythmias like Torsades de Pointes. Patients with a history of heart disease, recent heart attack, or those taking other QT-prolonging drugs must use Trazodone with extreme caution.
• Orthostatic Hypotension: Trazodone can cause a significant drop in blood pressure when standing up. This increases the risk of falls, particularly in the elderly. Patients should be advised to move slowly when changing positions.
• Serotonin Syndrome: The risk of serotonin syndrome is increased when Trazodone is combined with other serotonergic agents (e.g., SSRIs, SNRIs, triptans, tramadol). Symptoms can range from mild to life-threatening.
• Bleeding Risk: Trazodone may impair platelet aggregation, increasing the risk of bleeding events, especially when used with aspirin, NSAIDs (like ibuprofen), or anticoagulants (like warfarin).
• Activation of Mania/Hypomania: In patients with bipolar disorder, Trazodone may trigger a manic episode. A thorough screening for bipolar risk is necessary before starting treatment.

Healthcare providers may require the following monitoring during Trazodone therapy:

• Mental Status: Frequent checks for worsening depression or suicidal ideation.
• Blood Pressure: Regular monitoring, especially in patients prone to hypotension.
• Electrolytes: Periodic checks for sodium levels (hyponatremia risk).
• Liver/Kidney Function: Annual or semi-annual blood tests to ensure the body is processing the medication correctly.
• ECG: In patients with cardiac risk factors to monitor the QT interval.

Trazodone causes significant somnolence (drowsiness) and can impair judgment, thinking, and motor skills. You should not drive a car or operate dangerous machinery until you are certain how Trazodone affects you. This impairment is often most severe during the first few weeks of treatment.

Alcohol should be strictly avoided while taking Trazodone. Alcohol significantly increases the sedative effects of the drug, leading to extreme drowsiness, respiratory depression, and an increased risk of accidental injury or overdose.

Do not stop taking Trazodone abruptly. Sudden discontinuation can lead to a 'discontinuation syndrome,' characterized by anxiety, irritability, sleep disturbances, and nausea. Your healthcare provider will provide a tapering schedule to slowly reduce the dose over several weeks.

> Important: Discuss all your medical conditions, especially heart, liver, or kidney problems, with your healthcare provider before starting Trazodone.

• Monoamine Oxidase Inhibitors (MAOIs): Trazodone must not be used within 14 days of taking an MAOI (e.g., phenelzine, selegiline, tranylcypromine). Combining these can result in a fatal 'serotonin storm' or hypertensive crisis.
• Linezolid and IV Methylene Blue: These substances have MAOI-like properties and should not be started in a patient taking Trazodone due to the risk of Serotonin Syndrome.

• CYP3A4 Inhibitors: Drugs like ketoconazole, ritonavir, and clarithromycin block the enzyme that breaks down Trazodone. This leads to much higher levels of Trazodone in the blood, significantly increasing the risk of toxicity and side effects.
• CYP3A4 Inducers: Drugs like carbamazepine, phenytoin, and rifampin speed up the metabolism of Trazodone, which can make the medication less effective or ineffective.
• CNS Depressants: Opioids, benzodiazepines (like alprazolam), and sleep medications (like zolpidem) have additive sedative effects with Trazodone, which can lead to dangerous levels of respiratory depression and sedation.
• QT-Prolonging Drugs: Combining Trazodone with medications like amiodarone, ziprasidone, or certain antibiotics (moxifloxacin) increases the risk of life-threatening heart rhythm problems.

• SSRIs/SNRIs: While sometimes used together under strict supervision, the combination of Trazodone with drugs like fluoxetine or venlafaxine increases the risk of Serotonin Syndrome.
• Warfarin and NSAIDs: Trazodone can increase the risk of gastrointestinal bleeding when taken with blood thinners or anti-inflammatory drugs like aspirin or naproxen.
• Digoxin and Phenytoin: Trazodone may increase the serum levels of these medications, requiring more frequent blood level monitoring to prevent toxicity.

• Grapefruit and Grapefruit Juice: Grapefruit is a potent inhibitor of the CYP3A4 enzyme. Consuming grapefruit while taking Trazodone can lead to dangerously high levels of the drug in your system. It is best to avoid grapefruit entirely during treatment.
• High-Fat Meals: While taking Trazodone with food is recommended to reduce nausea, a very high-fat meal may significantly increase the absorption of the drug, potentially leading to increased side effects like dizziness.

• St. John’s Wort: This herbal supplement increases the risk of Serotonin Syndrome when combined with Trazodone.
• 5-HTP and L-Tryptophan: These supplements increase serotonin levels and should be avoided to prevent Serotonin Syndrome.
• Valerian and Kava: These sedative herbs can worsen the drowsiness caused by Trazodone, increasing the risk of falls and cognitive impairment.

• Urine Drug Screens: Trazodone and its metabolite mCPP may cause false-positive results for amphetamines or LSD on some rapid urine drug screening tests. If you are required to take a drug test, inform the testing facility that you are taking Trazodone so that a more specific confirmatory test (like GC/MS) can be performed.

For each interaction, the primary management strategy is dose adjustment and close clinical monitoring by a healthcare professional.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to avoid dangerous interactions.

There are several conditions where the use of Trazodone is strictly prohibited due to the risk of life-threatening complications:

• Hypersensitivity: Patients with a known allergy to Trazodone hydrochloride or any of the inactive ingredients in the tablet (such as lactose or specific dyes) must not take this medication. An allergic reaction can manifest as anaphylaxis, which is a medical emergency.
• MAOI Use: As previously mentioned, the use of Trazodone within 14 days of a Monoamine Oxidase Inhibitor is strictly contraindicated due to the risk of Serotonin Syndrome.
• Acute Recovery Phase of Myocardial Infarction (Heart Attack): Trazodone should not be used in patients immediately following a heart attack. The drug's potential to cause arrhythmias and orthostatic hypotension can place undue stress on a recovering heart muscle.

These are conditions where the benefits of Trazodone must be carefully weighed against the risks, and use should only occur under close specialist supervision:

• Bipolar Disorder: Because Trazodone can induce mania, it should be used with extreme caution in patients with a history of bipolar disorder or a family history of mania.
• Pre-existing Cardiac Disease: Patients with congestive heart failure, a history of QT prolongation, or bradycardia (slow heart rate) are at higher risk for cardiac side effects.
• Seizure Disorders: While rare, antidepressants can lower the seizure threshold. Trazodone should be used cautiously in patients with epilepsy or other conditions that increase seizure risk.
• Angle-Closure Glaucoma: Trazodone can cause pupillary dilation (mydriasis), which may trigger an acute attack of angle-closure glaucoma in susceptible individuals.
• Renal or Hepatic Disease: Severe impairment in liver or kidney function requires careful dose titration and monitoring.

There is no significant evidence of cross-sensitivity between Trazodone and other major classes of antidepressants like SSRIs or TCAs. However, patients who have had severe reactions to other phenylpiperazine derivatives should be monitored closely.

> Important: Your healthcare provider will evaluate your complete medical history, including any underlying conditions, before determining if Trazodone is a safe option for you.

Trazodone is classified as FDA Pregnancy Category C (under the older system). This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• First Trimester: Data is limited, but there is no clear evidence of an increased risk of major congenital malformations.
• Third Trimester: Use of antidepressants, including SARIs, during the third trimester may increase the risk of neonatal complications, such as persistent pulmonary hypertension of the newborn (PPHN) or neonatal withdrawal symptoms (irritability, feeding difficulties, and respiratory distress).
• Risk-Benefit: Trazodone should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Untreated depression also carries significant risks for both the mother and the baby.

Trazodone and its metabolites are excreted into human breast milk in small amounts. While the amount ingested by the infant is generally low, there is a risk of sedation in the nursing infant. Healthcare providers typically recommend monitoring the baby for excessive sleepiness or poor feeding. The decision to breastfeed while taking Trazodone should be made in consultation with a pediatrician and an obstetrician.

Trazodone is not approved for use in children or adolescents. The primary concern is the black box warning regarding increased suicidality in this age group. If a specialist determines that Trazodone is necessary for an adolescent (off-label), the patient must be monitored with extreme vigilance for any changes in mood, self-harming behaviors, or aggression.

The elderly are particularly vulnerable to the side effects of Trazodone.

• Fall Risk: Due to sedation and orthostatic hypotension, Trazodone is listed on the Beers Criteria as a potentially inappropriate medication for older adults unless other options are exhausted.
• Clearance: Renal and hepatic clearance often decrease with age, leading to higher drug concentrations.
• Hyponatremia: Older adults are at a higher risk of developing low sodium levels while taking Trazodone, especially if they are also taking diuretics.

In patients with mild to moderate renal impairment, Trazodone can generally be used at standard doses, but with increased monitoring. In cases of severe renal impairment or end-stage renal disease (ESRD), the drug's metabolites may accumulate, necessitating lower doses. Trazodone is not significantly cleared by hemodialysis.

Since Trazodone is extensively metabolized by the liver, patients with hepatic impairment (Child-Pugh Class B or C) require significant caution. Healthcare providers may start at 25% to 50% of the normal dose and monitor liver function tests (ALT, AST, Bilirubin) throughout treatment.

> Important: Special populations require individualized medical assessment and frequent follow-up with a healthcare professional.

Trazodone is a multifaceted serotonergic agent. Its primary mechanism involves the potent antagonism of 5-HT2A receptors and moderate inhibition of the serotonin reuptake transporter (SERT). By blocking 5-HT2A receptors, Trazodone prevents the 'over-stimulation' of certain pathways that can lead to anxiety and sexual dysfunction, which are common with SSRIs. Additionally, it acts as a partial agonist at 5-HT1A receptors, which may contribute to its anxiolytic effects. Beyond serotonin, Trazodone is a potent antagonist at alpha-1 adrenergic receptors and histamine H1 receptors, which accounts for its sedative and hypotensive properties.

The pharmacodynamic effects of Trazodone are dose-dependent. At low doses (25-100 mg), its action is dominated by H1 and alpha-1 antagonism, leading to sedation without significant antidepressant activity. At higher therapeutic doses (150-600 mg), the SERT inhibition and 5-HT2A antagonism become more pronounced, providing the antidepressant effect. Tolerance to the sedative effect may develop over several weeks, whereas the antidepressant effect typically persists.

| Parameter | Value |

|---|---|

| Bioavailability | 65% to 80% (Increased with food) |

| Protein Binding | 89% to 95% |

| Half-life | 5 to 9 hours (Terminal phase) |

| Tmax | 1 hour (Fasting); 2 hours (With food) |

| Metabolism | Hepatic (Primarily CYP3A4) |

| Excretion | Renal (70-75%), Fecal (20%) |

• Molecular Formula: C19H22ClN5O·HCl
• Molecular Weight: 408.32 g/mol
• Solubility: Sparingly soluble in water; soluble in alcohol.
• Structure: Trazodone is a triazolopyridine derivative. It consists of a phenylpiperazine chain linked to a triazolopyridine ring system.

Trazodone is the prototypical SARI (Serotonin Receptor Antagonist and Reuptake Inhibitor). While it shares some similarities with Nefazodone (another SARI), it is distinct from SSRIs like Prozac or TCAs like Amitriptyline due to its unique receptor binding profile and lack of anticholinergic activity.